These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 2946045)

  • 1. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
    Schally AV; Kook AI; Monje E; Redding TW; Paz-Bouza JI
    Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1985 Apr; 82(8):2498-502. PubMed ID: 3157990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological findings in the rat prostate cancer model during treatment with a luteinizing hormone-releasing hormone agonist and novantrone.
    Paz-Bouza JI; Schor NA; Monje E; Redding TW; Schally AV
    Prostate; 1987; 10(4):291-302. PubMed ID: 2955293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules.
    Redding TW; Schally AV; Tice TR; Meyers WE
    Proc Natl Acad Sci U S A; 1984 Sep; 81(18):5845-8. PubMed ID: 6237365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
    Redding TW; Schally AV
    Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
    Korkut E; Bokser L; Comaru-Schally AM; Groot K; Schally AV
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):844-8. PubMed ID: 1992476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
    Yano T; Pinski J; Szepeshazi K; Milovanovic SR; Groot K; Schally AV
    Prostate; 1992; 20(4):297-310. PubMed ID: 1351672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.
    Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1981 Oct; 78(10):6509-12. PubMed ID: 6458815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR; Radulovic S; Groot K; Schally AV
    Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
    Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH.
    Schally AV; Redding TW; Comaru-Schally AM
    Med Oncol Tumor Pharmacother; 1984; 1(2):109-18. PubMed ID: 6242477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations.
    Mason-Garcia M; Vigh S; Comaru-Schally AM; Redding TW; Somogyvari-Vigh A; Horvath J; Schally AV
    Proc Natl Acad Sci U S A; 1985 Mar; 82(5):1547-51. PubMed ID: 3156381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.
    Torres-Aleman I; Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1252-6. PubMed ID: 2858096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
    Radulovic S; Comaru-Schally AM; Milovanovic S; Schally AV
    Pancreas; 1993 Jan; 8(1):88-97. PubMed ID: 8093555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of analogs of luteinizing hormone-releasing hormone against x-radiation-induced testicular damage in rats.
    Schally AV; Paz-Bouza JI; Schlosser JV; Karashima T; Debeljuk L; Gandle B; Sampson M
    Proc Natl Acad Sci U S A; 1987 Feb; 84(3):851-5. PubMed ID: 2949328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
    Szepeshazi K; Milovanovic S; Lapis K; Groot K; Schally AV
    Breast Cancer Res Treat; 1992; 21(3):181-92. PubMed ID: 1355375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH.
    Schally AV; Redding TW; Comaru-Schally AM
    Prostate; 1983; 4(6):545-52. PubMed ID: 6226942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
    Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1983 Mar; 80(5):1459-62. PubMed ID: 6219395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.